首页 | 本学科首页   官方微博 | 高级检索  
     

中医辨证论治联合化疗治疗肺癌的临床研究
引用本文:代忠,田立霞,陶丰娟,姚克青,秦子舒. 中医辨证论治联合化疗治疗肺癌的临床研究[J]. 世界中医药, 2017, 0(7)
作者姓名:代忠  田立霞  陶丰娟  姚克青  秦子舒
作者单位:1 北京市朝阳区桓兴肿瘤医院综合科,北京,100122; 2 北京市朝阳区桓兴肿瘤医院中医科,北京,100122
基金项目:国家中医药重点专科建设项目(ZJ0901ZL020)
摘    要:目的:研究中医辨证论治联合化疗对肺癌近期疗效以及生命质量的影响,分析该治疗方式的价值。方法:随机选取2011年至2014年1月期间来我院进行治疗的肺癌患者90例,并分为2组,观察组使用中医辨证论治联合化疗,对照组使用单纯化疗,经过2个疗程的治疗后比较2组患者的近期疗效,并对治疗前后生命质量差异进行评价。结果:观察组治疗总有效率为93.33%,CR9例(20.00%)、PR33例(73.33%),这3项均高于对照组,对照组分别为77.78%、15.56%和62.22%,P0.05;观察组的1年生存率、2年生存率和3年生存率分别为68.89%、37.78%和17.78%均明显高于对照组的46.67%、24.44%、11.11%,P0.05;观察组的平均中位生存期为(18.2±5.1)个月也明显多于对照组的(13.0±3.7)个月,P0.05,观察组总不良反应更小;治疗后观察组的生理情况、社会家庭情况、情感、功能和肺癌症状评分分别为(19.3±3.5)、(20.5±3.1)、(17.6±2.8)、(19.0±3.7)和(25.0±4.7)远远大于对照组,P0.05。结论:中医辨证论治联合化疗是治疗肺癌的有效方案,较单一化疗大大提高了患者的生存期,并有效缓解疼痛提高生命质量。

关 键 词:中医辨证论治;化疗;肺癌
收稿时间:2017-06-10

Clinical Study on Treatment of Lung Cancer with TCM Syndrome Differentiation Combined with Chemotherapy
Dai Zhong,Tian Lixi,Tao Fengjuan,Yao Keqing,Qin Zishu. Clinical Study on Treatment of Lung Cancer with TCM Syndrome Differentiation Combined with Chemotherapy[J]. World Chinese Medicine, 2017, 0(7)
Authors:Dai Zhong  Tian Lixi  Tao Fengjuan  Yao Keqing  Qin Zishu
Affiliation:1 General Department, Cancer Hospital of HuaXing ChaoYang District Beijing, Beijing 100010, China; 2 Chinese tradition medicine department, Cancer Hospital of HuaXing ChaoYang District Beijing, Beijing 100010, China
Abstract:To study the effect of traditional Chinese medicine syndrome differentiation combining with chemotherapy on the recent curative effect of lung cancer as well as quality of life of lung cancer patients, and to evaluate this treatment.Methods:A total of 90 patients with lung cancer who were treated in our hospital from January 2011 to January 2014 were randomly divided into two groups. The study group was treated by chemotherapy combined with TCM syndrome differentiation. The control group was treated by chemotherapy only. After two courses of treatment The recent curative effects of the two groups were compared, and the differences in quality of life before and after treatment were evaluated. Results:In study group, the total effective rate was 93.33%, CR was 9 (20.00%) and PR was 33 (73.33%), while the control group was 77.78%, 15.56% and 62.22%, respectively (P<0.05). The 1-year survival rate, 2-year survival rate and 3-year survival rate were 68.89%, 37.78% and 17.78% respectively in the study group,and they were significantly higher than those in the control group(46.67%, 24.44%, 11.11%, P<0.05). The medium survival time was (18.2±5.1) months,which was significantly higher than those in the control group (13.0±3.7 months, P<0.05), the total adverse reactions were lesser in the study group; all kinds of scores of the study group after treatment (the physiological condition scores 19.3±3.5, family condition scores 20.5±3.1, emotion scores 17.6±2.8, function scores 19.0±3.7 and symptom scores 25.0±4.7) were significantly better than those in the control group (P<0.05). Conclusion:Combination of chemotherapy and TCM syndrome differentiation is an effective treatment for lung cancer, which greatly improves the survival time of patients, relieves pain and improves the quality of life of patients.
Keywords:TCM syndrome differentiation   Chemotherapy   Lung cancer
本文献已被 CNKI 等数据库收录!
点击此处可从《世界中医药》浏览原始摘要信息
点击此处可从《世界中医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号